Pulse Biosciences Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call for March 31, 2022

Pulse Biosciences Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call for March 31, 2022




Pulse Biosciences Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call for March 31, 2022

HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the fourth quarter and full year of 2021 after market close on Thursday, March 31, 2022. Company management will host a corresponding conference call beginning at 1:30pm Pacific Time.

Investors interested in listening to the conference call may do so by dialing 1-877-705-6003 for domestic callers or 1-201-493-6725 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The CellFX® System is the first commercial product to harness the distinctive advantages of NPS technology to treat a variety of applications for which an optimal solution remains unfulfilled. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. Visit pulsebiosciences.com to learn more.

To stay informed about the CellFX System, please visit CellFX.com and sign-up for updates.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Contacts

Investors:
Pulse Biosciences

Sandra Gardiner, EVP and CFO

510.241.1077

IR@pulsebiosciences.com
or

Gilmartin Group

Philip Trip Taylor

415.937.5406

philip@gilmartinir.com

Media:
Tosk Communications

Nadine D. Tosk

504.453.8344

press@pulsebiosciences.com